Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections
A controlled human trial reveals how preexisting antibodies influence dengue virus replication and immune responses, offering insights to develop safer, more broadly protective vaccines against all four dengue strains. The post Human Dengue Study Reveals How Preexisting Immunity Shapes Secondary Infections appeared first on GEN - Genetic Engineering and Biotechnology News .
An estimated 100-400 million people contract dengue, also known as break-bone fever, each year, posing a significant health threat to roughly half of the world's population. Dengue is prevalent in tropical and subtropical regions, and prevention primarily involves controlling the mosquito vector that transmits the virus. A new Phase I trial provides insights into how preexisting immunity and anti-dengue antibodies impact the severity of secondary dengue infections.
The study, published in Science Translational Medicine, reveals that individuals with antibodies that boost viral replication experience higher viral counts, reduced CD8-bearing T cells, and stronger acute immune responses. Conversely, those with antibodies against the viral nonstructural protein 1 display more balanced immune responses, leading to better control of viremia and the development of enduring, potent B and T cells.
These findings could inform the development of broadly protective vaccines that induce long-lasting dengue immunity.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
